Last updated on April 2019

A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder

Brief description of study

This study will evaluate the safety and tolerability of brexpiprazole (OPC-34712) in the treatment of subjects with bipolar I disorder. All subjects will receive a starting dose of brexpiprazole which will be titrated up in subsequent visits.

Detailed Study Description

While the availability of atypical antipsychotics have increased the therapeutic options available, there remains a need for safer and more effective therapies in the treatment of manic and depressive episodes of bipolar I disorder. Brexpiprazole's specific receptor activity profile likely correlates with its established efficacy in schizophrenia and major depressive disorder, and may prove to be an effective target for the treatment of acute mania of bipolar I disorder.

Clinical Study Identifier: NCT03287869

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.